Original Article
Autologous Bone Marrow Transplantation versus Intensive Consolidation Chemotherapy for Acute Myeloid Leukemia in Childhood
N Engl J Med 1996; 334:1428-1434May 30, 1996
- Abstract
Background
The value of autologous bone marrow transplantation in the treatment of children with acute myeloid leukemia (AML) is unknown. We compared autologous bone marrow transplantation with intensive consolidation chemotherapy as treatments for children with AML in first remission.
Methods
We induced remission with one course of daunorubicin, cytarabine, and thioguanine, followed by one course of high-dose cytarabine (3 g per square meter of body-surface area for six doses). Patients in remission after the second course of induction therapy were eligible for randomization. Between June 1988 and March 1993, 552 of 649 enrolled patients who could be evaluated (85 percent) entered remission. A total of 209 patients were not eligible for randomization; of the remaining 343 patients, 232 were randomly assigned to receive six courses of intensive chemotherapy (117 patients) or autologous transplantation (115 patients). Of the original 649 patients, 189, including 21 with Down's syndrome, were nonrandomly assigned to receive intensive chemotherapy.
Results
The mean (±SE) rates of event-free survival and overall survival for the entire group at three years were 34±2.5 percent and 42±2.6 percent, respectively. For patients who were randomly assigned to one of the two treatment groups, the rates of event-free survival three years after randomization were not significantly different in the two groups when examined by intention-to-treat analysis: 36±5.8 percent for the intensive-chemotherapy group as compared with 38±6.4 percent for the autologous-transplantation group; and the relative risk of treatment failure for the chemotherapy group as compared with the autologous-transplantation group was 0.81 (P = 0.20 by the log-rank test; 95 percent confidence interval, 0.58 to 1.12). Overall survival at three years followed a similar pattern. There was a lower relapse rate (31 percent vs. 58 percent, P<0.001) but a higher rate of treatment-related mortality (15 percent vs. 2.7 percent, P = 0.005) in the group treated with autologous transplantation than in the intensive-chemotherapy group. The event-free survival at three years for the nonrandomized intensive-chemotherapy group was 39±5.1 percent, and for a contemporaneous group of patients each of whom received a histocompatible bone marrow transplant from a sibling, it was 52±8.0 percent.
Conclusions
Treatment of children with AML in first remission with either autologous bone marrow transplantation or intensive chemotherapy prolongs event-free survival equally.
Media in This Article
Figure 1
Treatment Plan and Patient Assignments in the Study.Figure 2
Event-free Survival from the Time of Randomization or Assignment to Allogeneic Bone Marrow Transplantation.Article Activity
- Article
Chemotherapy can induce a remission in up to 85 percent of children with acute myeloid leukemia (AML).1-7 However, most patients relapse, and the long-term event-free survival ranges from 29 to 45 percent.1-7
The high rates of relapse in these children prompted the use of intensified chemotherapy and bone marrow transplantation after the initial remission. Among children with AML who receive allogeneic bone marrow transplants from histocompatible siblings, approximately 55 percent can be cured.8,9 However, less than 20 percent of children in the United States have suitable family donors for allogeneic transplantation.10 Another strategy, autologous bone marrow transplantation,11,12 has been evaluated in nonrandomized trials conducted in patients with AML in first remission. The results have been encouraging but ambiguous, because of biases in patient selection.13-15 We therefore undertook a multicenter, randomized trial to assess autologous transplantation in children with AML in first remission. Our results do not show a significant advantage of autologous bone marrow transplantation over intensive consolidation chemotherapy.
Methods
Eligibility
Patients under 21 years of age with previously untreated AML or isolated granulocytic sarcoma (chloroma) were eligible for the study. Patients with secondary AML were permitted to register for evaluation of the initial response but not for randomization at the time of remission. Morphologic classification followed the French–American–British system and was centrally reviewed.
Randomization
After giving informed consent, all patients were registered in the study prospectively. Patients who did not enter remission after the second course of induction chemotherapy were withdrawn from the study. Patients with histocompatible sibling donors were offered allogeneic bone marrow transplantation. The remaining patients were eligible for random assignment to either autologous transplantation or intensive consolidation chemotherapy, provided that they reaffirmed their intention to accept the randomized treatment, that financial support for autologous transplantation was available, and that there was a bed available at 1 of the 16 transplantation centers of the Pediatric Oncology Group. The randomization procedure was aimed at balancing the marginal totals of each morphologic subtype of AML.
Treatment
Induction therapy was given in two courses. The first course consisted of 45 mg of daunorubicin per square meter of body-surface area per day on days 1, 2, and 3; 100 mg of cytarabine per square meter per day by continuous infusion on days 1 through 7; and 100 mg of thioguanine per square meter per day, orally, on days 1 through 7; this was followed by high-dose cytarabine (3 g per square meter as a 3-hour infusion, every 12 hours for six doses).7 The second course of this treatment started on day 15 if the bone marrow showed residual leukemia; otherwise, it was begun when the absolute neutrophil count was 1000 per cubic millimeter or higher and the platelet count was 100,000 per cubic millimeter or higher. Intrathecal cytarabine (40 mg per square meter) was given on days 1 and 8 of the first course of induction therapy. Additional intrathecal cytarabine was given on days 12 and 19 to patients who had central nervous system leukemia at the time of diagnosis. Patients who entered remission (defined as having M1 marrow [<5 percent blasts] or M2a marrow [5 to 15 percent blasts]) were eligible for randomization. After randomization, all the patients received one course of etoposide (250 mg per square meter per day) on days 1, 2, and 3; azacytidine (300 mg per square meter per day) on days 4 and 5; and intrathecal cytarabine (40 mg per square meter) on days 1 and 7. The combination of etoposide and azacytidine was chosen as a consolidation therapy because of its low hematopoietic toxicity16 and hence the lower risk of serious infections in patients waiting for marrow transplantation. At this point the patients received either intensive chemotherapy, autologous transplantation, or allogeneic transplantation, depending on their treatment group.
Intensive Consolidation Chemotherapy
Patients assigned to receive intensive chemotherapy received six additional courses of therapy, each administered successively at three-week intervals or when the absolute neutrophil count was at least 1000 per cubic millimeter and the platelet count was at least 100,000 per cubic millimeter. The first drug course consisted of 45 mg of daunorubicin per square meter on day 1 and cytarabine as in the second induction course; the second course consisted of daunorubicin for two days and cytarabine and thioguanine for five days, with drug doses as in the first induction course; the third course consisted of etoposide and azacytidine, with drug doses as described above; the fourth course consisted of high-dose cytarabine, as in the second induction course; the fifth course was the same as the second course; and the sixth course was the same as the third. The cumulative dose of daunorubicin was 350 mg per square meter. Local radiotherapy was permitted for patients with central nervous system or extracranial mass lesions.
Autologous Bone Marrow Transplantation
Patients who were to undergo autologous transplantation had to be in complete remission after the consolidation course of etoposide and azacytidine and free of disseminated fungal disease. The protocol required harvesting the patient's bone marrow 6 to 12 weeks after the start of etoposide and azacytidine. To eliminate myeloblasts, the harvested marrow was treated under sterile conditions for 30 minutes with perfosfamide (4-hydroperoxycyclophosphamide) at a concentration of 100 μg per milliliter and an incubation hematocrit of 5 to 10 percent.
Patients were prepared for autologous marrow transplantation with 4 mg of busulfan per square meter per day, administered orally every six hours, on days 9, 8, 7, and 6 before transplantation and 50 mg of cyclophosphamide per kilogram, given intravenously, on days 5, 4, 3, and 2 before transplantation. After a day of rest, the cryopreserved marrow was thawed and infused (day 0). All patients received phenytoin (on days 11 through 4 before transplantation) as prophylaxis against seizures.
Allogeneic Bone Marrow Transplantation
Allogeneic transplantation was not a primary focus of this study because many Pediatric Oncology Group centers offer this treatment to any patient with a histocompatible family donor. The preparative regimen consisting of busulfan and cyclosphosphamide was strongly recommended, but a variety of conditioning regimens were used.
Statistical Analysis
It was necessary to have at least 150 randomized patients in order to achieve a power of 80 percent at the 0.05 significance level to detect a difference of 20 percentage points (40 percent vs. 60 percent) in event-free survival two years after randomization between patients who underwent autologous transplantation and those who received intensive consolidation chemotherapy.
Event-free survival was defined as the length of time until the first event — that is, treatment failure (relapse or failure to enter remission) or death. Overall survival was defined as the length of time until death. Calculations of event-free and overall survival for the entire group started from the date of registration; for the randomized groups they started from the date of randomization. Actuarial curves showing event-free and overall survival were constructed according to the Kaplan–Meier method.17 The relative risks were estimated with the Cox proportional-hazards model.18 Findings with respect to event-free and overall survival were tested for statistical significance by the log-rank test,19 according to the intention-to-treat principle. All P values reported in this article are two-sided.
Results
Between June 1988 and March 1993, 666 patients, 1 day to 20.9 years of age, were registered. Seventeen could not be evaluated, because of wrong diagnoses (10), major protocol violations (3), or withdrawal before induction therapy was completed because of toxicity or a parent's refusal of further therapy (4). Of the 649 patients who could be evaluated, 552 (85 percent) entered remission (507 had M1 marrow and 45 had M2a marrow). Death accounted for 26 of the 97 induction failures (27 percent); the other 71 patients who failed to enter remission had resistant disease. Figure 1Figure 1
Treatment Plan and Patient Assignments in the Study. shows the numbers of patients at each stage of treatment; 209 were not eligible for randomization because a suitable donor was available for allogeneic transplantation (89) or because of nonprotocol autologous transplantation (18), secondary AML (5), insufficient funds (64), lack of beds at a Pediatric Oncology Group transplantation institution (14), death before randomization (6), withdrawal due to drug toxicity (5), relapse before randomization (5), or other reasons (3). Thus, 343 of the 552 patients (62 percent) who entered remission were eligible for randomization. Of these, 232 (68 percent) were randomly assigned to a treatment group — 117 to the intensive-chemotherapy group and 115 to the autologous-transplantation group. The remaining 111 patients (32 percent), including 21 children with Down's syndrome, or their parents declined randomization.Clinical and Disease Characteristics
The two randomized groups had similar distributions of clinical, morphologic, and cytogenetic features (Table 1Table 1
Characteristics of the Patients in Remission after Induction Therapy.), except for a slight excess of extramedullary disease in the autologous-transplantation group. A stratified log-rank test adjusting for extramedullary disease failed to show a significant difference in event-free survival between the randomized groups (P = 0.21).Patterns of Treatment Failure in Randomized Patients
Table 2Table 2
Patterns of Treatment Failure. summarizes the reasons some patients did not complete the randomized treatment and shows the patterns of failure. More than a third of the patients (44 of 115, or 38 percent) assigned to autologous transplantation did not receive the intended treatment. Twenty-one patients relapsed before their marrow could be harvested. The parents of 14 patients chose intensive chemotherapy after randomization, 3 patients had disseminated fungal sepsis, the families of 5 opted for allogeneic transplantation, and 1 was lost to follow-up. The outcomes of these patients were included with those of the autologous-transplantation group in the intention-to-treat analysis. In contrast, only four patients (3.4 percent) assigned to intensive chemotherapy changed treatment options. The number of treatment-related deaths was significantly higher after autologous transplantation (11 of 71, or 15 percent) than after chemotherapy (3 of 113, or 2.7 percent; P = 0.005).Event-Free and Overall Survival
For all eligible patients, the mean (±SE) rates of event-free and overall survival at three years were 34±2.5 percent and 42±2.6 percent, respectively. The estimated event-free survival three years after randomization, according to the intention-to-treat analysis, was 36±5.8 percent in the intensive-chemotherapy group and 38±6.4 percent in the autologous-transplantation group (P = 0.20) (Figure 2Figure 2
Event-free Survival from the Time of Randomization or Assignment to Allogeneic Bone Marrow Transplantation.). The relative risk of treatment failure was 0.81 (95 percent confidence interval, 0.58 to 1.12) for the chemotherapy group as compared with the autologous-transplantation group. The rates of event-free and overall survival at three years for the nonrandomized chemotherapy group were 39±5.1 percent and 49±5.2 percent, respectively.The estimated rates of overall survival three years after randomization (Figure 3Figure 3
Overall Survival from the Time of Randomization or Assignment to Allogeneic Bone Marrow Transplantation.) for the chemotherapy and autologous-transplantation groups were 44±6.0 percent and 40±6.1 percent, respectively (P = 0.10 by the log-rank test), with a relative risk of death of 0.75 (95 percent confidence interval, 0.53 to 1.06) for the chemotherapy group as compared with the autologous-transplantation group.Children with Down's Syndrome
As the study evolved, the superior survival of children with Down's syndrome became evident,20 and thereafter the vast majority of these patients were assigned to receive chemotherapy, according to their physicians' preference. Thus, of 27 children with Down's syndrome who entered remission, 26 received intensive chemotherapy and 1 underwent allogeneic transplantation. Patients with Down's syndrome as a group had a three-year event-free survival of 77±2.1 percent. Removal of these patients (and three with isolated cases of granulocytic sarcoma) from the randomized groups did not alter the results (three-year event-free survival was 37 percent and 34 percent, respectively, for the autologous-transplantation and intensive-chemotherapy groups; P = 0.28).
Allogeneic Transplantation
Sixteen percent of the patients entering remission (89 of 552) had histocompatible donors and their families opted for allogeneic transplantation. The event-free survival three years after randomization was marginally better for the children who underwent allogeneic transplantation (52±8 percent) than for those given intensive consolidation chemotherapy (P = 0.06) and significantly better than that for children who underwent autologous transplantation (P = 0.01 by the log-rank test) (Figure 2). Overall survival after allogeneic transplantation was similar to that after intensive consolidation chemotherapy (P = 0.15) but superior to that after autologous transplantation (P = 0.007) (Figure 3).
Autologous Transplantation
The protocol called for bone marrow to be harvested 42 days after the consolidation course of etoposide and azacitidine (with a maximal allowable delay of 84 days). In actuality, the median time from randomization to the harvesting of marrow was 49 days (range, 21 to 106). In three patients, the marrow was harvested more than 84 days after treatment with etoposide and azacytidine. Delays were due for the most part to an unexpected biphasic pattern of recovery of blood counts after consolidation therapy. As a result, the interval between the consolidation therapy and the harvesting of bone marrow exceeded the minimal target of 42 days in 76 percent of the patients (it was more than 84 days in 20 percent of the patients).
The length of time until engraftment (defined as an absolute neutrophil count of more than 500 per cubic millimeter and a platelet count of more than 50,000 per cubic millimeter) ranged from 11 to 445 days or more (median, 43). Eleven patients died before engraftment. One received marrow from a sibling donor because of nonengraftment of autologous marrow, and backup autologous marrow was used in one patient.
Discussion
High-dose chemotherapy or allogeneic bone marrow transplantation after the induction of remission has improved the survival of children with AML. The limited availability of histocompatible family donors and the encouraging results obtained with autologous transplantation in refractory AML prompted several trials of autologous transplantation in adults with AML who were in their first remissions.13-15,20-26 Our results, when analyzed on an intention-to-treat basis, did not show that autologous transplantation was superior to intensive consolidation chemotherapy in prolonging event-free survival.
We encountered important problems in our study. A relatively large proportion (32 percent) of eligible patients were not randomized. After randomization to the autologous-transplantation group, 18 percent of the patients dropped out, often because they had relapses before the marrow could be harvested, and among the patients who actually received autologous transplants, the treatment-related mortality was 15 percent.
Other investigators have also encountered these difficulties. In a recent European study of AML,26 35 percent (139 of 393) of patients who were in remission and who did not have histocompatible donors could not be randomized; an additional 26 percent (33 of 125) assigned to undergo autologous transplantation did not complete the planned therapy. Stevens et al. reported that 30 percent of patients in remission in a British study of childhood AML could not be randomized.27 The unusually high rate of relapse before marrow harvest in our study may have been related to the slow recovery of the peripheral blood count after the course of consolidation therapy with etoposide and azacytidine. The death rate of 15 percent from toxic effects in patients who received autologous marrow grafts was related to the slow engraftment of perfosfamide-purged bone marrow.
Zittoun et al. have recently reported that treatment of adults with AML in first remission with autologous transplantation (with unpurged marrow) resulted in better outcomes than intensive consolidation chemotherapy.26 In their study, patients were randomized after the first consolidation course, whereas we randomized our patients after they completed induction chemotherapy. Moreover, there were a total of four courses of chemotherapy in the study by Zittoun et al. and nine in our study. These differences in the study design and the characteristics of patients (children vs. adults) preclude any comparisons between the two studies.
Three trials of autologous transplantation in children with AML have been reported.27-29 Amadori et al. found no significant difference in event-free survival five years after randomizaton between 37 patients who underwent chemotherapy (27 percent) and 35 who underwent autologous transplantation with unpurged marrow (21 percent).28 In Children's Cancer Group Study 2861, allogeneic transplantation was compared with autologous transplantation with the use of perfosfamide-purged marrow.29 The rate of event-free survival three years after transplantation was 51 percent among 58 patients who underwent autologous transplantation, and 55 percent among 17 who underwent allogeneic transplantation. The authors of the Medical Research Council's AML 10 trial,27 conducted in 347 children, concluded that allogeneic transplantation or autologous transplantation after four courses of intensive chemotherapy offered no survival advantage.
Finally, a comment is in order with respect to overall survival in this study as compared with that in other recent AML trials in children. Both the Medical Research Council trial27 and the Berlin–Frankfurt–Münster 87 study of 307 children30 reported overall survival of approximately 50 percent, as compared with 42±2.6 percent in our study. These differences may reflect different characteristics of the patients and the use of a more intensive induction regimen in the Medical Research Council and Berlin–Frankfurt–Münster trials. Intensification of induction chemotherapy can influence survival, regardless of post-remission therapy.31
Supported in part by grants (CA-29691, CA-20549, CA-03161, CA-29139, CA-28476, CA-29281, CA-32053, CA-25408, CA-31566, and CA-41573) from the National Cancer Institute.
We are indebted to Ms. Julie Nucci for her assistance in preparing this manuscript and to Mary Opel and Rita Russo.
Source Information
From the Children's Hospital of Michigan, Barbara Ann Karmanos Cancer Institute, and Wayne State University, Detroit (Y.R.); Emory University, Atlanta (A.M.Y.); the Pediatric Oncology Group Statistical Office and the Department of Statistics, University of Florida, Gainesville (M.N.C.); Baylor College of Medicine, Texas Children's Hospital, Houston (C.P.S.); the H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla. (J.K.); the University of Florida, Shands Teaching Hospital, Gainesville (J.G.-P.); the University of Alabama at Birmingham, Birmingham (A.C.); the Hurley Medical Center, Flint, Mich. (S.I.); the Midwest Children's Cancer Center, Medical College of Wisconsin, and the Children's Hospital of Wisconsin, Milwaukee (B.C.); and the Dana–Farber Cancer Institute and Children's Hospital, Boston (H.J.W.).
Address reprint requests to Dr. Ravindranath at the Pediatric Oncology Group, 645 N. Michigan Ave., Chicago, IL 60611.
Other contributing authors were Curt I. Civin, M.D. (Johns Hopkins Oncology Center, Baltimore); Mary V. Gresik, M.D. (Baylor College of Medicine, Pathology Department, Houston); and Susana Raimondi, Ph.D. (St. Jude Children's Research Hospital, Memphis, Tenn.). Additional participating Pediatric Oncology Group institutions and their principal investigators are listed in the Appendix.
Appendix
The following institutions and principal investigators also participated in the Pediatric Oncology Group: Alberta Pediatric Oncology Consortium, Edmonton, Alta., Canada — M. Coppes; All Children's Hospital, St. Petersburg, Fla. — J. Barbosa; Boston Floating Hospital, Boston — C. Kretschmar; Bowman Gray School of Medicine, Winston-Salem, N.C. — A. Chauvenet; Brooke Army Medical Center, Fort Sam Houston, Tex. — T. Pick; Cancer Center of Hawaii, Honolulu — R. Wilkinson; Carolinas Medical Center, Charlotte, N.C. — B. Golembe; Children's Hospital and Health Center, San Diego, Calif. — R. Kadota; Children's Hospital, Greenville Health System, Greenville, S.C. — C. Stroud; Children's Hospital of New Orleans, New Orleans — R.P. Warrier; Children's Memorial Hospital, Chicago — M. Kletzel; Christ Hospital and Medical Center, Oak Lawn, Ill. — S. Salvi; City of Hope National Medical Center, Duarte, Calif. — R. Chilcote; Cook–Fort Worth Children's Medical Center, Fort Worth, Tex. — P. Bowman; Dana–Farber Cancer Institute, Boston — H. Grier; Dartmouth–Hitchcock Medical Center, Lebanon, N.H. — E. Larsen; Duke University, Durham, N.C. — J. Kurtzberg; East Carolina University School of Medicine, Greenville, N.C. — T. Holbrook; Fairfax Hospital, Falls Church, Va. — J. Greenberg; Hackensack Medical Center, Hackensack, N.J. — M. Harris; Joe DiMaggio Children's Hospital at Memorial, Hollywood, Fla. — P. Sprinz; Johns Hopkins University, Baltimore — C. Schwartz; Kaiser Permanente Medical Center, Santa Clara, Calif. — L. Young; Keesler Air Force Medical Center, Santa Clara, Calif. — T. Abshire; MDA Cancer Center, Orlando, Fla. — V. Giusti; Maine Children's Cancer Program, Portland — C. Hurwitz; Massachusetts General Hospital, Boston — W. Ferguson; McGill University, Montreal — M. Whitehead; Medical College of Virginia, Richmond — E.C. Russell; Medical University of South Carolina, Charleston — J. Laver; Miami Children's Hospital, Miami — E. Escalon; Mount Sinai School of Medicine, New York — J. Lipton; Naval Regional Medical Center, San Diego, Calif. — D. Reardon; Nemours Children's Clinic, Jacksonville, Fla. — P. Pitel; Oklahoma University Health Sciences Center, Oklahoma City — R. Nitschke; Rhode Island Hospital, Providence — E. Forman; Roswell Park Memorial Institute, Buffalo, N.Y. — M. Brecher; Rush–Presbyterian–St. Luke's Medical Center, Chicago — A. Green; Sacred Heart Children's Hospital, Pensacola, Fla. — T. Jenkins; St. Christopher's Hospital, Philadelphia — E. Douglass; St. Francis Regional Medical Center, Wichita, Kans. — D. Rosen; St. John Hospital, Detroit — H. Sawaf; St. Joseph's Cancer Insitute, Tampa, Fla. — C. Tebbi; St. Vincent Hospital, Green Bay, Wis. — D. Ganick; Stanford University, Palo Alto, Calif. — M. Link; State University of New York at Syracuse, Syracuse — R. Dubowy; Swiss Pediatric Oncology Group, Bern, Switzerland — H. Wagner; Tripler Army Medical Center, Tripler, Hawaii — S. Reddoch; University of Alabama, Birmingham — R. Castleberry; University of Arizona Health Sciences Center, Tucson — J. Hutter; University of Arkansas, Little Rock — D. Becton; University of California at Davis, Sacramento — J. Ducore; University of California at San Diego, San Diego — F. Kung; University of Florida, Gainesville — P. Mehta; University of Kansas, Kansas City — T. Vats; University of Massachusetts Medical School, Worcester — M. Schwenn; University of Miami School of Medicine, Miami — S. Toledano; University of Mississippi Medical Center, Jackson — J. Pullen; University of Missouri, Columbia — N. Hakami; University of Puerto Rico, San Juan — N. Barrios; University of Rochester Medical Center, Rochester, N.Y. — R. Duerst; University of South Alabama, Mobile — Y.-M. Yang; University of South Florida, Tampa — E. Hvizdala; University of Texas, San Antonio — P.J. Thomas; University of Texas at Galveston, Galveston — M. Haggard; University of Texas, Southwestern Medical School, Dallas — G. Buchanan; University of Vermont College of Medicine, Burlington — J. Dickerman; University of Virginia, Charlottesville — P. de Alarcon; Walter Reed Army Medical Center, Washington, D.C. — D. Maybee; Warren Clinics, Tulsa, Okla. — G. Kirkpatrick; Washington University School of Medicine, St. Louis — T. Vietti; West Virginia University Health Science Center, Charleston — K. Starling; West Virginia University Health Services Center, Morgantown — A.K. Ritchey; Wilford Hall Air Force Medical Center, Lackland Air Force Base, Tex. — T. Trippet; Yale University School of Medicine, New Haven, Conn. — J. Van Hoff.
- References
References
1
Weinstein HJ ,Mayer RJ ,Rosenthal DS ,Coral FS ,Camitta BM ,Gelber RD . Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983;62:315-319
Web of Science | Medline2
Grier HE ,Gelber RD ,Camitta BM , et al. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 1987;5:1026-1032
Web of Science | Medline3
Creutzig U ,Ritter J ,Riehm H , et al. Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood 1985;65:298-304
Web of Science | Medline4
Steuber CP ,Civin C ,Krischer J , et al. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. J Clin Oncol 1991;9:247-258
Web of Science | Medline5
Nesbit ME Jr ,Buckley JD ,Feig SA , et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol 1994;12:127-135
Web of Science | Medline6
Woods WG ,Ruymann FB ,Lampkin BC , et al. The role of timing high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer 1990;66:1106-1113
CrossRef | Web of Science | Medline7
Ravindranath Y ,Steuber CP ,Krischer J , et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991;9:572-580
Web of Science | Medline8
Sanders JE ,Thomas ED ,Buckner CD , et al. Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update. Blood 1985;66:460-462
Web of Science | Medline9
Bostrom B ,Brunning RD ,McGlave P , et al. Bone marrow transplantation for acute nonlymphocytic leukemia in first remission: analysis of prognostic factors. Blood 1985;65:1191-1196
Web of Science | Medline10
Graham-Pole J . Treating acute lymphoblastic leukaemia after relapse: bone marrow transplantation or not? Lancet 1989;2:1517-1518
CrossRef | Web of Science | Medline11
Yeager AM ,Kaizer H ,Santos GW , et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986;315:141-147
Full Text | Web of Science | Medline12
Appelbaum FR ,Clift RA ,Buckner CD , et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 1983;61:949-953
Web of Science | Medline13
Gorin NC ,Aegerter P ,Auvert B , et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990;75:1606-1614
Web of Science | Medline14
McMillan AK ,Goldstone AH ,Linch DC , et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990;76:480-488
Web of Science | Medline15
Lowenberg B ,Verdonck LJ ,Dekker AW , et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990;8:287-294
Web of Science | Medline16
Hakami N ,Look AT ,Steuber PC , et al. Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1987;5:1022-1025
Web of Science | Medline17
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:475-481
CrossRef | Web of Science18
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22019
Peto R ,Peto J . Asymptomatically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-206
CrossRef | Web of Science20
Ravindranath Y ,Abella E ,Krischer JP , et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992;80:2210-2214
Web of Science | Medline21
Cassileth PA ,Andersen J ,Lazarus HM , et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993;11:314-319
Web of Science | Medline22
Burnett AK ,Tansey P ,Watkins R , et al. Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission. Lancet 1984;2:1068-1070
CrossRef | Web of Science | Medline23
Appelbaum FR ,Fisher LD ,Thomas ED . Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988;72:179-184
Web of Science | Medline24
Reiffers J ,Gaspard MH ,Maraninchi D , et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol 1989;72:57-63
CrossRef | Web of Science | Medline25
Schiller GJ ,Nimer SD ,Territo MC ,Ho WG ,Champlin RE ,Gajewski JL . Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992;10:41-46
Web of Science | Medline26
Zittoun RA ,Mandelli F ,Willemze R , et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217-223
Full Text | Web of Science | Medline27
Stevens RF ,Hann IM ,Burnett AK ,Goldstone AH ,Wheatley K ,Gray RG . Improved outcome in paediatric acute myeloid leukemia: results of the MRC AML 10 trial. Med Pediatr Oncol 1994;23:172-172 abstract.28
Amadori S ,Testi AM ,Arico M , et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993;11:1046-1054
Web of Science | Medline29
Woods WG ,Kobrinsky N ,Buckley J , et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. J Clin Oncol 1993;11:1448-1457
Web of Science | Medline30
Creutzig U ,Harbott J ,Sperling C , et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995;86:3097-3108
Web of Science | Medline31
Woods WG ,Kobrinsky N ,Buckley J , et al. Timing intensive induction therapy improves post-remission outcome in acute myeloid leukemia (AML) irrespective of the use of bone marrow transplantation (BMT). Blood 1994;84:Suppl 1:232a-232a abstract.
Web of Science
- Citing Articles (85)
Citing Articles
1
Jeffrey W. Taub, Yaddanapudi Ravindranath. (2011) What's up with down syndrome and leukemia-A lot!. Pediatric Blood & Cancer 57:1, 1-3
CrossRef2
Nicolas Novitzky, Valda Thomas, Cecile du Toit, Andrew McDonald. (2011) Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis. Biology of Blood and Marrow Transplantation 17:6, 875-884
CrossRef3
C E Hill-Kayser, J P Plastaras, Z Tochner, E Glatstein. (2011) TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplantation 46:4, 475-484
CrossRef4
D. Niewerth, U. Creutzig, M. B. Bierings, G. J. L. Kaspers. (2010) A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116:13, 2205-2214
CrossRef5
Jeffrey E. Rubnitz, Brenda Gibson, Franklin O. Smith. (2010) Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America 24:1, 35-63
CrossRef6
Dae Hyoung Lee, Nak Gyun Chung, Bin Cho, Hack Ki Kim, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Hoon Kook, Tai Ju Hwang, Ho Joon Im, Jong Jin Seo, Hyeon Jin Park. (2010) Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea. Journal of Korean Medical Science 25:1, 9
CrossRef7
Hyoung Jin Kang, Ji Won Lee, Sang Hyeok Kho, Min Jeong Kim, Young Jin Seo, Hyery Kim, Hee Young Shin, Hyo Seop Ahn. (2010) High Transcript Level of FLT3 Associated with High Risk of Relapse in Pediatric Acute Myeloid Leukemia. Journal of Korean Medical Science 25:6, 841
CrossRef8
John Gregory, Haesook Kim, Todd Alonzo, Rob Gerbing, William Woods, Howard Weinstein, Lois Shepherd, Charles Schiffer, Frederick Appelbaum, Cheryl Willman, Peter Wiernik, Jacob Rowe, Martin Tallman, James Feusner. (2009) Treatment of children with acute promyelocytic leukemia: Results of the first North American intergroup trial INT0129. Pediatric Blood & Cancer 53:6, 1005-1010
CrossRef9
John Gregory, James Feusner. (2009) Acute promyelocytic leukemia in childhood. Current Oncology Reports 11:6, 439-445
CrossRef10
Ana C. Xavier, Yubin Ge, Jeffrey W. Taub. (2009) Down Syndrome and Malignancies: A Unique Clinical Relationship. The Journal of Molecular Diagnostics 11:5, 371-380
CrossRef11
H. Edwards, C. Xie, K. M. LaFiura, A. A. Dombkowski, S. A. Buck, J. L. Boerner, J. W. Taub, L. H. Matherly, Y. Ge. (2009) RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood
CrossRef12
Dae-Hyoung Lee, Young-Joo Kwon, Jihyang Lim, Yonggoo Kim, Kyungja Han, Nak-Gyun Chung, Dae-Chul Jeong, Bin Cho, Hack-Ki Kim. (2009) Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatric Transplantation 13:2, 210-216
CrossRef13
L'Aurelle A. Johnson, Julie A. Ross. (2008) Host factors and consequence of chemotherapy in pediatric cancer patients. Pediatric Blood & Cancer 51:3, 320-326
CrossRef14
Gunn Elisabeth Vist, Dianne Bryant, Lyndsay Somerville, Trevor Birminghem, Andrew D Oxman, Gunn Elisabeth Vist. 2008. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. .
CrossRef15
Maureen M. O’Brien, Normal J. Lacayo. (2008) Acute Leukemia in Children. Disease-a-Month 54:4, 202-225
CrossRef16
Y Ge, K M LaFiura, A A Dombkowski, Q Chen, S G Payton, S A Buck, S Salagrama, A E Diakiw, L H Matherly, J W Taub. (2008) The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 22:3, 521-529
CrossRef17
Rupert Handgretinger, Joanne Kurtzberg, R. Maarten Egeler. (2008) Indications and Donor Selections for Allogeneic Stem Cell Transplantation in Children with Hematologic Malignancies. Pediatric Clinics of North America 55:1, 71-96
CrossRef18
Jeffrey E. Rubnitz, Brenda Gibson, Franklin O. Smith. (2008) Acute Myeloid Leukemia. Pediatric Clinics of North America 55:1, 21-51
CrossRef19
Fred H. Laningham, Larry E. Kun, Wilburn E. Reddick, Robert J. Ogg, E. Brannon Morris, Ching-Hon Pui. (2007) Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 49:11, 873-888
CrossRef20
Shana S. Jacobs, Linda C. Stork, Bruce C. Bostrom, Ray Hutchinson, John Holcenberg, Gregory H. Reaman, Gary Erdmann, Janet Franklin, Joseph P. Neglia, Seth M. Steinberg, Frank M. Balis, Peter C. Adamson. (2007) Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatric Blood & Cancer 49:3, 250-255
CrossRef21
S Neudorf, J Sanders, N Kobrinsky, T A Alonzo, A Buxton, J D Buckley, W Howells, S Gold, D R Barnard, J DeSwarte, D Kalousek, B J Lange, W G Woods. (2007) Autologous bone marrow transplantation for children with AML in first remission. Bone Marrow Transplantation 40:4, 313-318
CrossRef22
Courtney F. Tsao, Jignesh Dalal, Charles Peters, Celia Gonzalez, Gregory L. Kearns. (2007) Azacitidine Pharmacokinetics in an Adolescent Patient With Renal Compromise. Journal of Pediatric Hematology/Oncology 29:5, 330-333
CrossRef23
Gunn Elisabeth Vist, Kåre Birger Hagen, PJ Devereaux, Dianne Bryant, Doris Tove Kristoffersen, Andrew D Oxman, Gunn Elisabeth Vist. 2007. Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate. .
CrossRef24
Ronald M. Tan, Thuan Chong Quah, LeLe Aung, Shen Liang, Richard C. Kirk, Allen E.J. Yeoh. (2007) Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol. Pediatric Blood & Cancer 48:3, 262-267
CrossRef25
Seung Tai Kim, Chul Won Jung, Jeeyun Lee, Jung Mi Kwon, Sung Young Oh, Byeong-Bae Park, Hyo Rak Lee, Hyun Jung Kim, Kihyun Kim, Won Seog Kim, Jin Seok Ahn, Won Ki Kang, Keunchil Park. (2007) Postremission therapy for acute myeloid leukemia in the first remission. Leukemia & Lymphoma 48:5, 937-943
CrossRef26
Denise M. Oliansky, J. Douglas Rizzo, Peter D. Aplan, Robert J. Arceci, Louis Leone, Yaddanapudi Ravindranath, Jean E. Sanders, Franklin O. Smith, Fiona Wilmot, Philip L. McCarthy, Theresa Hahn. (2007) The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Children: An Evidence-Based Review. Biology of Blood and Marrow Transplantation 13:1, 1-25
CrossRef27
Mouhab Ayas, Amal Al-Seraihi, Mohamad Al-Mahr, Abdullah Al-Jefri, Assim Belgaumi, Ibrahim Elhassan, Hassan El-Solh. (2006) The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen. Pediatric Blood & Cancer 47:7, 926-930
CrossRef28
William G. Woods. (2006) Curing childhood acute myeloid leukemia (AML) at the half-way point: Promises to keep and miles to go before we sleep. Pediatric Blood & Cancer 46:5, 565-569
CrossRef29
D-C Liang, T-T Chang, K-H Lin, D-T Lin, M-Y Lu, S-H Chen, H-C Liu, M-T Lin, M-T Lee, S-G Shu, T-K Chang, J-S Chen, C-C Hsiao, I-J Hung, Y-L Hsieh, R-L Chen, S-N Cheng, W-H Chang, C-H Lee, K-S Lin. (2006) Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 20:1, 136-141
CrossRef30
Andrew G. Muntean, Yubin Ge, Jeffrey W. Taub, John D. Crispino. (2006) Transcription factor GATA-1 and Down syndrome leukemogenesis. Leukemia & Lymphoma 47:6, 986-997
CrossRef31
A Pession, R Rondelli, G Basso, C Rizzari, A M Testi, F Fagioli, P De Stefano, F Locatelli. (2005) Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 19:12, 2043-2053
CrossRef32
Y Perel, A Auvrignon, T Leblanc, G Michel, Y Reguerre, J-P Vannier, J-H Dalle, V Gandemer, C Schmitt, F Méchinaud, O Lejars, C Piguet, G Couillaud, B Pautard, J Landman-Parker, I Thuret, N Aladjidi, A Baruchel, G Leverger. (2005) Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 19:12, 2082-2089
CrossRef33
B E S Gibson, K Wheatley, I M Hann, R F Stevens, D Webb, R K Hills, S S N De Graaf, C J Harrison. (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19:12, 2130-2138
CrossRef34
G Kardos, C M Zwaan, G J L Kaspers, S S N de-Graaf, E S J M de Bont, A Postma, J P M Bökkerink, R S Weening, A van der Does-van den Berg, E R van Wering, C Korbijn, K Hählen. (2005) Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 19:12, 2063-2071
CrossRef35
Y Ravindranath, M Chang, C P Steuber, D Becton, G Dahl, C Civin, B Camitta, A Carroll, S C Raimondi, H J Weinstein. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:12, 2101-2116
CrossRef36
Edske ter Bals, Gertjan JL Kaspers. (2005) Treatment of childhood acute myeloid leukemia. Expert Review of Anticancer Therapy 5:5, 917-929
CrossRef37
Sema Anak, Ebru Tugrul Saribeyoglu, Hülya Bilgen, Aysegul Unuvar, Zeynep Karakas, Omer Devecioglu, Leyla Agaoglu, Gunduz Gedikoglu. (2005) Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: A single center experience. Pediatric Blood & Cancer 44:7, 654-659
CrossRef38
Hyoung Jin Kang, Seung-Hee Hong, In Hoo Kim, Byung-Kiu Park, Kyou Sup Han, Han Ik Cho, Hee Young Shin, Hyo Seop Ahn. (2005) Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. Leukemia Research 29:6, 617-623
CrossRef39
A M Slats, R M Egeler, A van der Does-van den Berg, C Korbijn, K Hählen, W A Kamps, A J P Veerman, C M Zwaan. (2005) Causes of death – other than progressive leukemia – in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia
CrossRef40
Y. Ge, M. L. Stout, D. A. Tatman, T. L. Jensen, S. Buck, R. L. Thomas, Y. Ravindranath, L. H. Matherly, J. W. Taub. (2005) GATA1, Cytidine Deaminase, and the High Cure Rate of Down Syndrome Children With Acute Megakaryocytic Leukemia. JNCI Journal of the National Cancer Institute 97:3, 226-231
CrossRef41
Hye Ryoung Yi, Dong Kyun Han, Hee Jo Baek, Young Ok Kim, Seok Joo Kim, Eun Song Song, Hoon Kook, Tai Ju Hwang. (2005) Hematopoietic Stem Cell Transplantation in Pediatric Acute Myelogenous Leukemia: Relevance of the Stem Cell Source to the Transplant Outcome. The Korean Journal of Hematology 40:4, 242
CrossRef42
Massimo Berger, Ivana Ferrero, Elena Vassallo, Luca Gastaldo, Francesca Carraro, Eleonora Biasin, Enrico Madon, Franca Fagioli. (2005) STEM CELL TRANSPLANTATION AS CONSOLIDATION THERAPY FOR CHILDREN IN FIRST-REMISSION AML. Pediatric Hematology-Oncology 22:7, 597-608
CrossRef43
Jeffrey W. Taub, Yubin Ge. (2005) Down syndrome, drug metabolism and chromosome 21. Pediatric Blood & Cancer 44:1, 33-39
CrossRef44
Ch. M. Zwaan, G. J. L. Kaspers. (2004) Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. British Journal of Haematology 127:3, 264-279
CrossRef45
L. L. Chan, M. E. Abdel-Latif, W. A. Ariffin, H. Ariffin, H. P. Lin. (2004) Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country. British Journal of Haematology 126:6, 799-805
CrossRef46
Soheil Meshinchi, Wendy M Leisenring, Paul A Carpenter, Ann E Woolfrey, Eric L Sievers, Jerald P Radich, Jean E Sanders. (2003) Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biology of Blood and Marrow Transplantation 9:11, 706-713
CrossRef47
John Gregory, James Feusner. (2003) Acute promyelocytic leukaemia in children. Best Practice & Research Clinical Haematology 16:3, 483-494
CrossRef48
Sverre O. Lie, Jonas Abrahamsson, Niels Clausen, Erik Forestier, Henrik Hasle, Liisa Hovi, Gudmundur Jonmundsson, Lotta Mellander, Goran Gustafsson. (2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. British Journal of Haematology 122:2, 217-225
CrossRef49
Apostolia-Maria Tsimberidou, Niki Stavroyianni, Nora Viniou, Maria Papaioannou, Maria Tiniakou, Theodoros Marinakis, Anastasia Skandali, Ioanna Sakellari, Xenophon Yataganas, . (2003) Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 97:7, 1721-1731
CrossRef50
Jennifer J. Clark, Franklin O. Smith, Robert J. Arceci. (2003) Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. Current Opinion in Hematology 10:1, 31-39
CrossRef51
Yaddanapudi Ravindranath. (2003) Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Current Opinion in Oncology 15:1, 23-35
CrossRef52
Eiichi Ishii, Hajime Kawasaki, Keiichi Isoyama, Minenori Eguchi-Ishimae, Mariko Eguchi. (2003) Recent Advances in the Treatment of Infant Acute Myeloid Leukemia. Leukemia & Lymphoma 44:5, 741-748
CrossRef53
Philip D. Hall, Bassem I. Razzouk, Tony E. Willoughby, Thomas W. McLean, Arthur E. Frankel. (2002) The Majority of Children and Adolescents With Acute Myeloid Leukemia Have Detectable Anti-DT388-GMCSF IgG Concentrations, but at Concentrations That Should Not Preclude In Vivo Activity. Journal of Pediatric Hematology/Oncology 24:7, 521-526
CrossRef54
Allen R. Chen, Todd A. Alonzo, William G. Woods, Robert J. Arceci. (2002) Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - An American view. British Journal of Haematology 118:2, 378-384
CrossRef55
Alan K. Burnett, Keith Wheatley, Anthony H. Goldstone, Richard F. Stevens, Ian M. Hann, John H. K. Rees, Georgina Harrison, . (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology 118:2, 385-400
CrossRef56
Ursula Creutzig, Dirk Reinhardt. (2002) current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A European view. British Journal of Haematology 118:2, 365-377
CrossRef57
Keith Wheatley. (2002) Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A statistician's view. British Journal of Haematology 118:2, 351-356
CrossRef58
Claudia Langebrake, Dirk Reinhardt, J??rg Ritter. (2002) Minimising the Long-Term Adverse Effects of Childhood Leukaemia Therapy. Drug Safety 25:15, 1057-1077
CrossRef59
Fernando Marco, Encarna Bureo, Arancha Bermúdez, Elena Fernández-Fontecha, Alberto Zubizarreta. (2001) Treatment of acute leukemia in children: recent advances and future challenges. Expert Review of Anticancer Therapy 1:3, 479-486
CrossRef60
David M. Loeb, Daniel C. Bowers, Curt I. Civin, Alan D. Friedman. (2001) Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. Medical and Pediatric Oncology 37:4, 365-371
CrossRef61
John P. Perentesis, Eric L. Sievers. (2001) Targeted Therapies for High-Risk Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America 15:4, 677-701
CrossRef62
Richard M Stone. (2001) Postremission therapy in adults with acute myeloid leukemia. Seminars in Hematology 38, 17-23
CrossRef63
Peter B. Langmuir, Richard Aplenc, Beverly J. Lange. (2001) Acute myeloid leukaemia in children. Best Practice & Research Clinical Haematology 14:1, 77-93
CrossRef64
Jeffrey W. Taub. (2001) Relationship of Chromosome 21 and Acute Leukemia in Children With Down Syndrome. Journal of Pediatric Hematology/Oncology 23:3, 175-178
CrossRef65
Esteban Abella, Yaddanapudi Ravindranath. (2000) Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation. Current Oncology Reports 2:6, 529-538
CrossRef66
A Verschuur. (2000) Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia a promising target for chemotherapy. European Journal of Cancer 36:5, 627-635
CrossRef67
Alan K Burnett, Jonathan Kell. (2000) High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia. Current Opinion in Oncology 12:2, 110-115
CrossRef68
Brad Spellberg, Gary J. Schiller. (1999) AUTOLOGOUS BONE MARROW TRANSPLANTATION IN ACUTE LEUKEMIA. Hematology/Oncology Clinics of North America 13:5, 919-938
CrossRef69
Lowenberg, Bob, Downing, James R., Burnett, Alan, . (1999) Acute Myeloid Leukemia. New England Journal of Medicine 341:14, 1051-1062
Full Text70
Alan K. Burnett. (1999) Tailoring the treatment of acute myeloid leukemia. Current Opinion in Hematology 6:4, 247
CrossRef71
(1999) Treatment of Acute Myeloid Leukemia. New England Journal of Medicine 340:18, 1436-1439
Full Text72
Jose A. Martinez-Climent, Javier Garcfa-Conde. (1999) Chromosomal Rearrangements in Childhood Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Pediatric Hematology/Oncology 21:2, 91-102
CrossRef73
Alan K. Burnett. (1999) Tailoring the treatment of acute myeloid leukemia. Current Opinion in Oncology 11:1, 14
CrossRef74
Cassileth, Peter A., Harrington, David P., Appelbaum, Frederick R., Lazarus, Hillard M., Rowe, Jacob M., Paietta, Elisabeth, Willman, Cheryl, Hurd, David D., Bennett, John M., Blume, Karl G., Head, David R., Wiernik, Peter H., . (1998) Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. New England Journal of Medicine 339:23, 1649-1656
Full Text75
Burnett, Alan K., . (1998) Transplantation in First Remission of Acute Myeloid Leukemia. New England Journal of Medicine 339:23, 1698-1700
Full Text76
Peter Jacobs. (1998) Myelodysplasia and the leukemias. Current Problems in Cancer 22:6, 384-464
CrossRef77
Straetmans, Herman, Van Bockstaele, Michaux, Hagemeijer, Ferrant. (1998) Haemopoietic defect and decreased expansion potential of bone marrow autografts from patients with acute myeloid leukaemia in first remission. British Journal of Haematology 101:3, 571-581
CrossRef78
Richard F. Stevens, Ian M. Hann, Keith Wheatley, Richard G. Gray, . (1998) Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. British Journal of Haematology 101:1, 130-140
CrossRef79
Alan K Burnett, Anthony H Goldstone, Richard MF Stevens, Ian M Hann, John KH Rees, Richard G Gray, Keith Wheatley. (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. The Lancet 351:9104, 700-708
CrossRef80
Louie Naumovski, Gary Martinovsky, Christopher Wong, Myron Chang, Yaddanapudi Ravendranath, Howard Weinstein, Gary Dahl. (1998) BCL-2 expression does not correlate with patient outcome in pediatric acute myelogenous leukemia. Leukemia Research 22:1, 81-87
CrossRef81
Hartmut Link, Hans-Jochem Kolb, Wolfram Ebell, Dieter Kurt Hossfeld, Axel Zander, Dietrich Niethammer, Hannes Wandt, Hans Grosse-Wilde, Ulrich W. Schaefer. (1997) Die Transplantation hämatopoetischer Stammzellen. Medizinische Klinik 92:9, 534-545
CrossRef82
RUTH LADENSTEIN, CHRISTINA PETERS, HELMUT GADNER. (1997) The Present Role of Bone Marrow and Stem Cell Transplantation in the Therapy of Children with Acute Leukemia. Annals of the New York Academy of Sciences 824:1 Challenges an, 38-64
CrossRef83
SVERRE O. LIE, GUDMUNDUR K. JONMUNDSSON, LOTTA MELLANDER, MARTTI A. SIIMES, MINNA YSSING, GÖRAN GUSTAFSSON. (1997) Chemotherapy of Acute Myelocytic Leukemia in Children. Annals of the New York Academy of Sciences 824:1 Challenges an, 84-90
CrossRef84
N. Cole, B.E. Gibson. (1997) High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Blood Reviews 11:1, 39-45
CrossRef85
AK Burnett, OB Eden. (1997) The treatment of acute leukaemia. The Lancet 349:9047, 270-275
CrossRef
